Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers

Annals of Clinical and Laboratory Science

Volumn 36, Issue 1, 2006, Pages 16-22

  Tang, Ping ^a   Wang, Xi ^a   Schiffhauer, Linda ^a   Wang, Jianmin ^b   Bourne, Patricia ^a   Yang, Qi ^a   Quinn, Andrew ^a   Hajdu, Steven I ^c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast carcinoma; Ductal carcinoma in situ; Intraductal carcinoma; Nuclear grade

Indexed keywords

ANTIBODY; CYTOKERATIN;

ARTICLE; BASAL CELL; BREAST CARCINOMA; CANCER GRADING; CARCINOMA IN SITU; CELL DIFFERENTIATION; DISEASE ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STEM CELL;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; HUMANS; IMMUNOASSAY; KERATINS; MAMMARY GLANDS, HUMAN; STEM CELLS; TUMOR MARKERS, BIOLOGICAL;

EID: 33646502692     PISSN: 00917370     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Silverstein MJ. Current controversies in ductal carcinoma in situ of the breast: Summary from the Lynn Sage breast cancer symposium. J Am Coll Surg 2003;197:115-118.
2. Leonard GD, Swain SM. Ductal carcinoma in situ, complexities and challenges. J Natl Cancer Inst 2004; 96:906-920.
3. Ceilley E, Jagsi R, Goldberg S, et al. The management of ductal carcinoma in situ in North America and Europe. Cancer 2004;101:1958-1967.
4. Silverstein MJ, Lagios MD, Craig PH, et al. A prognostic index for ductal carcinoma in situ of the breast. Cancer 1996;77:2267-2274.
5. Silverstein MJ. The University of Southern California/ Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 2003;186:337-343.
6. Lagio MD. Ductal carcinoma in situ. Pathology and treatment. Surg Clin North Am 1990;70:853-871.
7. Holland F, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994;11:167-180.
8. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma in situ. Lancet 1995;345:1154-1157.
9. Tang P, Seichberg S, Roberts B, et al. Ultrastructure of periductal area of comedo carcinoma in situ of the breast. Ann Clin Lab Sci 2001;31:284-290.
10. Cornfield DB, Palazzo JP, et al. Prognostic significance of multiple morphologic features and biological markers in ductal carcinoma in situ of the breast. A study of a large cohort of patients treated with surgery alone. Cancer 2004;100:2317-2327.
11. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. NEJM 2004;351:2817-2826.
12. Dupond WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. NEJM 1985; 312:146-151.
13. Lakhani SR. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 1999;187:272-278.
14. Singletary S. A working model for the time sequence of genetic changes in breast tumorigenesis. J Am Coll Surg 2002;194:202-216.
15. Buerger H, Otterbach F, Simon R, et al. Comparative genomic hybridization of ductal carcinoma in situ of the breast: evidence of multiple genetic pathways. J Pathol 1999;187:396-402.
16. Polyak K. On the birth of breast cancer. Biochim Biophys Acta 2001;1552:1-13.
17. Lacroix M, Toulon RA, Leclercq G. Stable "portrait" of breast tumors during progression: data from biology, pathology, and genetics. Endocrine-Related Cancer 2004;11:497-522.
18. Sontag L, Axelrod DE. Evaluation of pathways for progression of heterogeneous breast tumors. J Theoretical Biol 2005;232:179-189.
19. Boecker W, Moll R, Dervan P, et al. Usual ductal hyperplasia of the breast is a committed stem (progenitor) cell lesion distinct from atypical ductal hyperplasia and ductal carcinoma in situ. J Pathol 2002;198:458-467.
20. Megha T, Ferrari F, et al. p63 mutant in breast cancer. Correlation with cell kinetics and cell of origin. J Clin Pathol 2002;55:461-466.
21. Van de Rijn M, Perou CM, Tibshirani R, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-1996.
22. El-Rehim DMA, Finder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203:661-671.
23. Sortil T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinoma distinguish tumor subclasses with clinical implications. PNAS USA 2001;98: 10869-10874.
24. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. PNAS USA 2003;100:8418-8423.
25. Smith GH. Experimental mammary epithelial morphogenesis in an in vivo model: evidence for distinct cellular progenitors of the ductal and lobular phenotype. Breast Cancer Res Treat 1996;39:21-31.
26. Kordon EC, Smith H. An entire functional mammary gland may comprise the progeny from a single cell. Development 1998;125:1921-1930.
27. Diallo R, Schaefer KL, Poremba C, et al. Monoclonality in normal epithelium and in hyperplastic and neoplastic lesions of the breast. J Pathol 2001;193:27-32.
28. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. PNAS USA 2003;100:3983-3988.
29. Clayton H, Titley I, Vivanco MM, et al. Growth and differentiation of progenitor/stem cells derived from the human mammary gland. Exp Cell Res 2004;297:444-460.
30. Welm B, Behbod F, Goodell MA, et al. Isolation and characterization of functional mammary gland stem cells. Cell Prolif 2003;36(Suppl 1):17-32.
31. Petersen OW, Gudjonsson T, Villadsen R, et al. Epithelial progenitor cell lines as models of normal breast morphogenesis and neoplasia. Cell Prolif 2003;36(Suppl 1):33-44.
32. Clarke RB, Anderson E, Howell A, et al. Regulation of human breast epithelial stem cells. Cell Prolif 2003;36 (Suppl 1):45-58.
33. Smalley M, Ashwarth A. Stem cells and breast carcinoma: A field in transit. Nature Rev Cancer 2003;3:832-844.
34. Taylor-Papadimitriou J, Lane EB. Keratin expression in the mammary gland. In: The Mammary Gland: Development Regulation and Function (Daniel CW, Ed), Plenum Press, New York, 1987; pp 181-215.
35. Nagle RB, Bocker W, Davis JR, et al. Characterization of breast carcinoma by two monoclonal antibodies distinguishing myoepithelial from luminal epithelial cells. J Histochem Cytochem 1986;34:869-881.
36. Jaracsh ED, Nagle RB, Kaufmann M, et al. Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol 1988;19:276-289.
37. Tsubura A, Okada H, Senzaki H, et al. Keratin expression in the normal breast and in breast carcinoma. Histopathology 1991;18:517-522.
38. Bocker W, Moll R, Poremba C, et al. Common adult cells in the human breast give rise to glandular and myoepithelial cell lineages: A new cell biological concept. Lab Invest 2002;82:737-745.
39. Takei H, Iino Y, Horiguchi J, at al. Immunohistochemical analysis of cytokeratin #8 as a prognostic factor in invasive breast carcinoma. Anticancer Res 1995;15: 1101-1106.
40. Santini D, Ceccarelli C, Taffurelli M, et al. Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression. J Pathol 1996;179:386-391.
41. Korsching E, Packeisen J, Agelopoulos K, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002;82:1525-1533.